All In Biotech

Drug Trial Radar · NCT07766980

Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients

Last checked: Nov 20, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

20

Planned (sponsor's estimate)

Start

Jul 27, 2026

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
University of FloridaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This pilot study will investigate the potential efficacy of VM100, a nutritional supplement specifically formulated for patients with DMD, on quality of life and physical symptoms. Twenty patients (aged 8 an over) will be enrolled to undergo a 10-week placebo-controlled intervention with VM100. Outcomes will include validated questionnaires and qualitative interview to assess impact on mental, cognitive and mood related measures, as well as endurance and fatigue).

Conditions

  • Duchenne Muscular Dystrophy
  • Duchenne Disease
  • Muscular Dystrophy in Children
  • DMD
  • Muscular Dystrophy

Interventions

  • VM100 Nutritional SupplementDrug

    VM100 is an investigational dietary supplement formulated specifically for individuals with Duchenne muscular dystrophy. It contains ten naturally derived ingredients formulated using a proprietary technology to enhance bioavailability. The supplement is intended to support mitochondrial function, reduce inflammation and oxidative stress, improve cognitive function and mood, and promote overall quality of life. Participants will self-administer the supplement orally twice daily during the intervention period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in DMD Quality of Life Physical Symptoms Domain ScoreTime frame: Baseline, Weeks 2, 6, 8, and 10
  2. Changes in Mental Wellbeing assessed Warwick-Edinburgh Mental Well-being Scale ScoreTime frame: Baseline, Weeks 2, 6, 8, and 10
  3. Changes in Quality of Life assessed by PedsQL 4.0 Short Form (SF-15) Total ScoreTime frame: Baseline, Weeks 2, 6, 8, and 10

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of Florida

    Gainesville, Florida · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.